secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-221538
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar reports positive nomlabofusp data; all 6-month patients reach carrier-level FXN
--------------------------------------------------------------------------------

- 10/10 participants at 6 months achieved skin FXN >50% of healthy volunteer median (asymptomatic carrier levels).
- Directional improvement in mFARS, FARS-ADL, 9-HPT, MFIS vs worsening in natural history cohort after 1 year.
- Anaphylaxis occurred in 7 participants (all within first 6 weeks); starting dose regimen modified; FDA agreed.
- BLA submission seeking accelerated approval for nomlabofusp expected in Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312525221538/0001193125-25-221538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312525221538/d24800d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-221538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer